|
Market Cap (5-Jul) $6,838,995 (1,207th) |
Close (30-Jun) $0.200 |
Volume (30-Jun) 1,808,064 |
Shortsold (12-Jun) 8,499 (0.01%) (521st) |
|
52w High $0.100 |
52w Low $0.059 |
P/E - |
EPS 0 |
IXC released this announcement to the ASX on 9 April 2021, 16:55. The announcement is not marked as price sensitive, and is 2 page(s) in length and 248.2kb in size.
You can view all announcements from IXC and see how they appear on a price chart on the announcements page.
At the date of this announcement, IXC was 0.563% short sold according to ASIC data. It was ranked the 257th most shorted stock on the ASX. It remains ranked 521st as of the latest reported data (12 June 2025).
| Other Recent Announcements from IXC | |
|---|---|
| Phase III Clinical Trial Update and New IIH Market Analysis | 28 June 2023, 8:40 |
| Invex Granted European Orphan Drug Designation for TBI | 23 June 2023, 8:18 |
| Invex Receives Regulatory Approval for IIH EVOLVE in France | 21 April 2023, 8:17 |
| Change of Director's Interest Notice | 9 April 2021, 16:55 |
| Results of Meeting | 8 April 2021, 18:34 |
| Chairman's Address to Shareholders | 8 April 2021, 17:56 |
| Invex Files Pre-IND/Type B Meeting Request with US FDA | 31 March 2021, 8:52 |
You must be logged in to post a reply.
Invex Therapeutics Ltd 